# Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

> **NCT03749213** · PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- EGF-R Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT03749213
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2024-12-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749213, "Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03749213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*